First ‘gene silencing’ drug for Alzheimer’s disease shows promise

An exciting new genetic therapy for Alzheimer’s disease (AD) is safe and successfully lowered levels of the harmful tau protein known to cause the disease, in a world first trial at UCLH and UCL.

The trial, led by consultant neurologist Dr Catherine Mummery at the National Hospital for Neurology and Neurosurgery, represents the first time that a ‘gene silencing’ approach has been taken in dementia and in AD.

In this approach, the aim is to use a drug to ‘silence’ the gene coding for the tau protein – the microtubule-associated protein tau (MAPT) gene – with a drug called BIIB080, which is an antisense oligonucleotide. This prevents the gene being translated into the protein in a doseable, reversible way. This can then lower the production of that protein and alter the course of disease.

Further trials will be needed in larger groups of patients to determine whether this then leads to clinical benefit, but the phase 1 results published today in Nature Medicine are the first indication that this method has a biological effect.

There are currently no treatments targeting tau. The drugs aducanumab and lecanemab – recently approved for use in some situations by the FDA – target a separate disease mechanism in AD, the accumulation of amyloid plaques.

The phase 1 trial looked at the safety of MAPTRx, what it does to the body, and how well it targets the MAPT gene. It involved the UCL Dementia Research Centre, was supported by the NIHR UCLH Biomedical Research Centre, and took place at the NIHR UCLH Clinical Research Facility at Queen Square.

46 patients with an average age of 66 were enrolled in the trial which took place from 2017 to 2020. The trial looked at three doses of the drug, given by intrathecal injection (an injection into the nervous system via the spinal canal), compared with placebo.

Results show that the drug was well tolerated, with all patients completing the treatment period and over 90% completing the post-treatment period.

Patients in both the treatment and placebo groups experienced either mild or moderate side effects. The most common side effect was headache after injection of the drug. But no serious adverse events were seen in patients given the drug.

The research team also looked at levels of two forms of the tau protein in the central nervous system (CNS) – a reliable indicator of disease – over the duration of the study.

They found a greater than 50% reduction in levels of total tau and phosphor tau concentration in the CNS after 24 weeks in the two treatment groups which received the highest dose of the drug.

Dr Mummery said: “We will need further research to understand the extent to which the drug can slow progression of physical symptoms of disease and evaluate the drug in older and larger groups of people and in more diverse populations.

“But the results are a significant step forward in demonstrating that we can successfully target tau with a gene silencing drug to slow – or possibly even reverse – Alzheimer’s disease, and other diseases caused by tau accumulation in the future.”